TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: withdrawal occlusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: number of false-positive test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of re-consulting patients
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Urinary excretion of calcium over 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cardiovascular death or readmission
Endpoint domain: Mortality/survival
Primary endpoint: Initial NFT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SICI differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effectiveness of cognitive therapy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Renal function (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of chronic heart failure (CHF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean percent change in LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence to sodium restriction guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uveal effusion prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Construct validity of the IRES-3
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Basal forearm blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tinetti test
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Essen Questionnaire on Age and Sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: No reprogramming or magnet application
Endpoint domain: Adverse events/effects
Primary endpoint: Fusion rate and speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS (Visual Analog Scale)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Mean tissue concentrations of clindamycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean tissue concentrations of metronidazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of pancreatic necrotic infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: overall stability indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-colonoscopy peritonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in quantity of symptomatic drugs needed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Exhaled nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: tIgE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: craving during non-drinking moments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance of respiratory system improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: head shape outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of death or necrotizing enterocolitis (stage >=2)
Endpoint domain: Mortality/survival
Primary endpoint: Patient satisfaction with cosmetic outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse wound healing
Endpoint domain: Adverse events/effects
Primary endpoint: SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mechanical resistance to manipulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tooth sensitivity intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECG ST segment elevation disappearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Collateral flow index (CFI) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of clonal expansions of T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time spent on bCPAP initiation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: subjective pain level in low back area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elevation in liver enzymes (ALT, AST, SAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in ucOC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Combined endpoints of death and hospitalization due to HF
Endpoint domain: Mortality/survival
Primary endpoint: Number of days lost to death or hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Threshold (HPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-efficacy pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disclosure rates of HIV status to significant others
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Improvement in mNPQ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with prescribed physiotherapy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of malapposed stent struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stereopsis Acuity (SA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEF(25-75%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CF-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in illness cognitions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: need for clean intermittent self catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: rate of urinary retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: re-admission for bladder catheterization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: vascular resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: creatine kinase myocardial band isoenzyme peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: troponin T peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neutralizing antibody detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Resistance of LDL against oxidation (lag phase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean itching scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in gait cycle length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shortening of the stance phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lengthening of the swing phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic exposure to ethinylestradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Systemic exposure to levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total PISQ-12 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for web-based PISQ-12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SDS total score improvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: WHO-5 total score improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HDRS(17) work/activities improvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: survival free of major disability
Endpoint domain: Mortality/survival
Primary endpoint: decrease in NTX/creatinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No evidence of disease (NED) at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Immune responses (CD8+ and CD4+ T cell responses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BVAS decline at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: target-vessel MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: local adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Energy metabolism changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fractional synthesis rate of total liver protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free hepatic concentrations of alanine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free hepatic concentrations of essential amino acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting colonic volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postprandial small bowel water
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: T1 of the descending colon chyme
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: proportion of healed teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMDQ (Roland-Morris Disability Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PSFS (Patient-Specific Functional Scale)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: QVAS (Questionnaire for Visual Analog Scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in corticosteroid dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exacerbation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient activation improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rates of having one or more primary care visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Physical health related quality of life (HRQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of burnout syndrome
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: treatment response for alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low concentrations of lipid-soluble vitamins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severe anemia (hemoglobin <85 g/l)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: maximum hemoglobin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ferritin increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: transferrin saturation increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of variation in the scoring of the Cognitive Mini Examination
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: qADAM scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Microfilaridermia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of amicrofilaridermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viability of female adult worms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total IGF1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioactive IGF1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevation of troponin I or creatine kinase-MB above the upper limit of normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CSF CRH concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mood drop
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knee joint proprioception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in salivary bacterial levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cumulative failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean medication use reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: successful outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction or elimination of analgesic intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle weakness during statin therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathologic findings of myopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in IBS-SSS by ≥50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of pro-inflammatory and anti-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: imbalance in the complement system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: activity and intensity of phagocytosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: speed (m/sec)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stride length (m)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement in decision making
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Knowledge about options
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Discussion of medications
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Incidence of deep venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Emotional expressiveness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physiological reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Experience of unpleasant emotion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: frequency of sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: satisfaction with orgasms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sexual arousal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean surface laryngeal lag time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean surface laryngeal onset time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak effects at larynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health benefits of GS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative sufentanil consumption within 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCIA trigger times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores at various time points after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WMSI (Wall Motion Score Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Use of lipid-lowering medications (LLM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Short- and long-term mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: brachial artery flow-mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SF-36 Physical Functioning score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: emergence time from anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in intestinal flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean of good quality embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of fatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Combined clinical endpoint during the 12 month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunohistochemical staining positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characteristics of hypervascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in blood supply
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient reported impact of constipation on quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: post-operative VRS pain levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of cardiovascular death, nonfatal myocardial infarction, nonfatal cerebral infarction, and unstable angina
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in pain and disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability Assessment for Dementia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive anti‐AN1792 antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: relief of pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency of responses compatible with sexual intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: favourable global response rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overactive bladder symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indevus Urgency Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of physically agitated behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: participants' affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean SPID(48) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 15-year graft survival
Endpoint domain: Mortality/survival
Primary endpoint: Plasma Epinephrine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: TT time improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in total premenstrual symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in active behavioural coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in premenstrual distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hyperkalemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Need for catecholamines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: complete STR at 60 min after PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax for Zen-200
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax for Zen-200
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2a for Zen-200
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of symptomatic cerebral hemorrhage (SCH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of postoperative complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes